CLINICAL TRIAL: PIOGLITAZONE AS A TREATMENT FOR PATIENTS WITH SCHIZOPHRENIA

临床试验：吡格列酮治疗精神分裂症患者

• 批准号: 8166849
• 负责人: Hua Jin
• 金额: $ 0.62万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166849
• 关键词: Antipsychotic Agents; Cholesterol; Clinical Trials; Cognitive deficits; Computer Retrieval of Information on Scientific Projects Database; Funding; Glucose; Glucose tolerance test; Grant; HDL-triglyceride; High Density Lipoproteins; Institution; Learning; Measures; Memory; Odds Ratio; Patients; Performance; Pioglitazone; Placebos; Research; Research Personnel; Resources; Schizophrenia; Source; Testing; Triglycerides; United States National Institutes of Health; fasting glucose; glucose metabolism; impaired glucose tolerance; improved; indexing; lifestyle intervention

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Determine if Pioglitazone plus life-style intervention will be more effective than placebo plus lifestyle intervention in reducing triglyceride levels in antipsychotic treated schizophrenic patients with impaired (>150 mg/dL) or elevated (>200 mg/dL) triglyceride levels. Determine if Pioglitazone plus life style intervention will be more effective than placebo plus lifestyle intervention in increasing HDL and decreasing two atherosclerotic risk ratios (Total cholesterol/HDL and triglycerides/HDL). Determine if Pioglitazone plus life-style intervention will be more effective than placebo plus lifestyle intervention in reducing indices of impaired glucose metabolism (fasting glucose levels >100 mg/dL, Hb1Ac levels >6.4, 2 hr glucose values in glucose tolerance test >140 mg/dL). Determine if the degree of impaired glucose tolerance as assessed by fasting glucose levels and 2 hr glucose levels on glucose tolerance test will be significantly negatively correlated with immediate and delayed verbal memory performance (as measured by list learning and story recall on the RBANS.) Determine if the degree of improvement from impaired glucose tolerance (fasting glucose, and 2 hr glucose in glucose tolerance test)will be correlated with improved performance in verbal memory as measured by the tests noted in hypothesis. Determine if the degree of memory improvement (same day pre-glucose baseline vs. 2 hr) during GTT glucose load, on paired word and short story of the RANDT Memory Scale will be correlated with the degree of baseline cognitive deficit and the degree of impaired glucose tolerance.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此，可以在其他清晰的条目中表示。列出的机构是 对于中心，这不一定是调查员的机构。 确定Pioglitazone Plus LifeStyle干预是否比安慰剂加上生活方式干预更有效，以降低患有受损（> 150 mg/dl）抗精神病药治疗的精神分裂症患者的甘油三酸酯水平或升高（> 200 mg/dl）甘油三酸酯水平。 确定Pioglitazone Plus生活方式是否比安慰剂加上生活方式干预更有效，以增加HDL并降低两个动脉粥样硬化风险比（总胆固醇/HDL和甘油三酸酯/HDL）。 确定Pioglitazone Plus LifeStyle干预是否比安慰剂加上生活方式干预更有效/dl）。 确定通过禁食葡萄糖水平评估的葡萄糖耐受性受损程度以及在葡萄糖耐量测试中的2小时葡萄糖水平是否与立即和延迟的言语记忆表现显着相关（如RBAN上的列表学习和故事回忆所测量）。 确定葡萄糖耐受性受损（空腹葡萄糖和2小时葡萄糖测试中的2小时葡萄糖）的改善程度是否与通过假设中指出的测试所衡量的言语记忆的改善相关。 确定在GTT葡萄糖负载期间，在配对单词和兰特记忆量表的短篇小说中，在GTT葡萄糖负载期间的记忆力改善程度（同一天前基线和2小时）是否与基线认知缺陷的程度和障碍程度有关葡萄糖耐受性。